PF-Atlas › Clinical Trials › NCT07284459

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

PIPE-791 Dose A · Phase 2

Registry ID
NCT07284459
Phase
Phase 2
Status
Recruiting
Drug / intervention
PIPE-791 Dose A
Sponsor
Contineum Therapeutics
Start
2026-01-08
Enrollment
324
Locations
69

About this trial

This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.

View NCT07284459 on ClinicalTrials.gov →

Explore related

All PIPE-791 Dose A trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT07284459 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.